Torqur AG’s Bimiralisib Gel Shows Promise in Treating AKs
Torqur AG’s topical bimiralisib, a selective pan-PI3K/mTOR inhibitor, may help clear actinic keratosis (AK) lesions, according to interim Phase 2 results presented at the American Academy of Dermatology’s 2025 annual meeting in Orlando, FL. Specifically, 60% of trial patients experienced full or partial AK lesion clearance. Overactivation of the phosphoinositide 3-kinase (PI3K)/mechanistic target of the […]